HOME >> BIOLOGY >> NEWS
Alejandro Zaffaroni to receive 2006 Biotechnology Heritage Award

The Chemical Heritage Foundation (CHF) and the Biotechnology Industry Organization (BIO) will present the 8th Annual Biotechnology Heritage Award to Alejandro Zaffaroni, an outstanding pioneer of the biotechnology revolution and legendary entrepreneur with considerable scientific and business skills. The award will be presented at the plenary breakfast session from 7:30 to 9:00 a.m. on Monday, 10 April, at BIO 2006 at McCormick Place Convention Center in Chicago.

"Dr. Zaffaroni's scientific contributions, particularly in the area of drug delivery, have enhanced health care for people throughout the world," stated BIO president Jim Greenwood. "His steadfast commitment to research and development has earned him more than two dozen patents and the deep-founded respect of his colleagues."

"Alex Zaffaroni helped to guide Syntex to success in the 1950's, and has gone on to give the world a half-century of life-saving innovations through his commitment to novel drug delivery and his inspired entrepreneurship," said Arnold Thackray, president of CHF. "He embodies the spirit that is making biotechnology a living, thriving reality."

Alejandro Zaffaroni
Over a long and distinguished career, Zaffaroni has founded and cofounded many companies that have become world leaders in medical technology. A native of Montevideo, Uruguay, Zaffaroni joined Syntex Corporation in 1951. At the time, Syntex was a small chemical company in Mexico that was becoming prominent in steroid research. He subsequently played a key role in transforming Syntex into a major pharmaceutical company that pioneered the development of the birth control pill.

Zaffaroni developed controlled drug delivery technology, more commonly known as "the patch," and founded ALZA Corporation to bring this important technology to the world market. In addition to ALZA, Zaffaroni founded DNAX, Affymax, Affymetrix, Maxygen, SurroMed, and Alexza--all companies that developed and mar
'"/>

Contact: Neil Gussman
neilg@chemheritage.org
215-873-8262
Chemical Heritage Foundation
24-Apr-2006


Page: 1 2

Related biology news :

1. Carnegie Mellons Peter Adams receives EPA research grant
2. 2007 EURYI: 20 young researchers to receive Nobel Prize-sized awards for breakthrough ideas
3. Fedoroff, of Penn State, to receive National Medal of Science
4. Philadelphia ecologist receives top Mongolia honor
5. Nearly 90 percent of babies receive recommended newborn screening tests
6. VIB scientist receives major research grant
7. Maynard Olson receives $500,000 Gruber Genetics Prize
8. University of Cincinnati receives $1.7M to research molecular treatment of brain injury
9. UGA scientists receive $20M in federal bioenergy initiative
10. Wright State scientist receives grant to help clean up polluted American harbors
11. UCR biologist receives $1.75 million grant to study plant-threatening bacteria

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Alejandro Zaffaroni receive Biotechnology Heritage Award

(Date:3/20/2015)... 20, 2015 Research and Markets ... the "India Sensors Market Forecast and Opportunities ... The sensor market is projected to grow at ... Consumer electronics, automotive, industrial and healthcare sectors are ... country. In addition, adoption of MEMS technology in ...
(Date:3/20/2015)... Conn. , March 20, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... smart wallet is one of the products featured in ... March 20th at 11:00 PM EST on the DIY ... to Las Vegas , site of ...
(Date:3/19/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, announces its biometric payment technology, the Wocket® smart ... week on Washington DC,s Fox 5 ... "The Next Great Thing", host Laura Evans calls ... ,a really big breakthrough in mobile payment.,  ...
Breaking Biology News(10 mins):India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
(Date:4/16/2015)... MOSCOW , April 16, 2015 /PRNewswire/ ... (ChemRar), the Russian pharmaceutical investment and R&D ... announced collaboration for research, development and commercialization ... with the intention to stimulate ... industry.      (Logo: http://photos.prnewswire.com/prnh/20150416/739742-a) ,     ...
(Date:4/16/2015)... , April 16, 2015  AnaptysBio, Inc., a ... therapeutic antibodies, today announced the advancement of ... into IND-enabling studies. The Company,s anti-IL-36R therapeutic ... for generalized pustular psoriasis (GPP), an orphan ... need. ANB019 is wholly owned within AnaptysBio,s proprietary ...
(Date:4/16/2015)... , April 16, 2015 Avelas Biosciences, an ... improving cancer surgeries, announced today that it has initiated ... illuminator, AVB-620, in women with primary, non-recurrent breast cancer ... also welcomed the addition of Steven Chen , ... The open label, dose escalation study will enroll up ...
(Date:4/16/2015)... LAUSANNE , Switzerland ... Debiopharm International SA (Debiopharm), part of Debiopharm Group ™ ... prescription drugs that target unmet medical needs ... that preclinical data on the investigational compounds ... inhibitor) will be presented at the 2015 ...
Breaking Biology Technology:Lancet and ChemRar High Tech Center Have Announced a Partnership in the Development and Production of Novel Drugs in Russia 2AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 3
Cached News: